This agent approved for the prophylaxis of venous thromboembolism (VTE) in adults who are hospitalized for acute medical illness and at risk for thromboembolic complications due to moderate or severe restricted mobility and other VTE risk factors.

In a randomized, double-blind, multinational clinical trial comparing extended duration betrixaban to short duration enoxaparin for the prevention of VTE in 7513 acutely medically ill hospitalized individuals with VTE risk factors: associated with fewer events of proximal deep vein thrombosis, non-fatal pulmonary embolism, or VTE-related death (4.4%) than those taking enoxaparin (6%).

The most common adverse events with betrixaban were bleeding-related.

Leave a Reply

Your email address will not be published. Required fields are marked *